Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study);Estudio longitudinal de adherencia, satisfacción y efectividad del tratamiento antirretroviral administrado una vez al día, frente a dos veces al día, en una cohorte Española de infectados por el VIH (estudio CUVA: Cualquiera una vez al día)

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 3, 2008, Pages 127-134

  Viciana, Pompeyo ^a   Rubio, Rafael ^b   Ribera, Esteve ^c   Knobel, Hernando ^d   Iribarren, José A ^e   Arribas, José R ^f   Pérez Molina, José A ^g  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e HOSPITAL DONOSTIA   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Adherence; HAART; Once daily; Treatment satisfaction

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CONFIDENCE INTERVAL; DRUG EFFICACY; FAMILY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; SOCIAL SUPPORT; SPAIN; STRUCTURED QUESTIONNAIRE; TREATMENT OUTCOME; VIRUS LOAD; VISUAL ANALOG SCALE;

EID: 40949138197     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13116748     Document Type: Article

References (39)

1. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-7.
2. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
3. Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al; GEEMA Study Group. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS. 2002;16:605-13.
4. Knobel H, Rubio R, Miró JM, Gatell JM, Del Campo A. Adherence to antiretroviral therapy: The patient's perspective. 7th European Conference on Clinical Aspects and treatment of HIV-Infection. Lisboa, 1999. Abstract 857.
5. Moyle G. The APPT-1 Study: Assessing Patients' Preferred Treatments. 6th International Congress on Drug Therapy in HIV-Infection. Glasgow, 2002.
6. Bass D, Smith MF. HIV patients prefers once-daily regimens. 14th World AIDS Conference. Barcelona 2002. Abstract MoPeB3290.
7. Jordan J, Carranza J, Pathak D, Pilon T. Perceived influence of regimen characteristics on adherence. 4th International Congress on Drug Therapy in HIV Infection. Glasgow, 2000. Abstract P121.
8. Ena J, Pasquau F. Once-a-day highly active antiretroviral therapy: A systematic review. Clin Infect Dis. 2003;36:1186-90.
9. Taburet AM, Paci-Bonaventure S, Peytavin G, Molina JM. Once-daily administration of antiretrovirals. Pharmacokinetics of emerging therapies. Clin Pharmacokinet. 2003;42:1179-91.
10. Staszewski S, Haberl A, Carlebach A, Rottmann C, Millar V, Gute P. A simple, once-daily doping regimen for treating HIV-1 infection in intravenous drug users. HIV Medicine. 2000;1:162-3.
11. Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, et al; the Imea 011/ANRS 12-04 Study Group. Once-a-day highly active antiretroviral therapy in treatment-naïve HIV-1-infected adults in Senegal. AIDS. 2003;17:1017-22.
12. Farmer P, Leandro F, Mukherjee JS, Claude M, Nevil P, Smith-Fawki MC, et al. Community-based approaches to HIV treatment in resource-poor setting. Lancet. 2001;358:404-9.
13. Maggiolo F, Migliorino M, Maserati R, Pan A, Rizzi M, Provettoni G, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther. 2001;6:249-53.
14. Panel on Clinical Practices for Treatment of HIV convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 29, 2004. AIDSinfo web site (http://AIDSinfo. nih.gov).
15. Panel de expertos de Gesida. Plan Nacional Sobre el SIDA. Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (Enero 2007). Enferm Infecc Microbiol Clin. 2007;25:32-53.
16. Claxton AJ, Cramer J, Pierre C. A systematic review of the associations between dose regimens and medication compilance. Clin Ther. 2001;23:1296-310.
17. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis. Clin Ther. 2002;24:302-16.
18. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 2001;15:1369-77.
19. Knobel H, Guelar A. Estrategias para optimizar la adherencia al tratamiento antirretroviral. Intervenciones en la pauta terapéutica. Enferm Infecc Microbiol Clin. 2004;22:106-12.
20. Harris M, Back D, Kewn S, Jutha S, Marina R, Montaner JS. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS. 2002;16:1196-7.
21. Van Heeswijk RP, Velkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, et al. The steady-state pharmacokinetics of nevirapine during once-daily and twice daily doping in HIV-infected individuals. AIDS. 2000;14:77-82.
22. Boffito M, Dickinson L, Hill A, Higgs C, Fletcher C, Johnson C, et al. Saquinavir/ritonavir pharmacokinetics in HIV-positive subjects: 1,000/100 mg BD vs 1,600/100 and 2,000/100 mg once-daily (OD). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois, 2003. Abstract A-1612.
23. Gathe Jr JC, Ive P, Word R, Schurmann D, Bellos NC, De Jesús E, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18:35:22-32.
24. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis. 2000;182:599-602.
25. Molina JM, Ferchal F, Rancinan C, Yeni P, Rozenbaum W, Journot V, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in treatment naïve HIV-infected adults: 96-week follow-up of the ANRS 091 trial. En: Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, 2001. Abstract P221.
26. Arribas JR, De Jesús E, Campo R, Jemsek J, Gallart JE, Gazzard B, et al; AND the study 934 Team. The combination of tenofovir DF, emtricitabine and efavirenz has significantly greater response vs fixed dose zidovudine/lamivudine and efavirenz in antiretroviral naive patients: A 24-week preliminary analysis. 7th International Congress on Drug Therapy in HIV infection. Glasgow, 2004.
27. Maggiolo F, Arici C, Gregis G, Quinzan G, Ripamonti D, Ravasio L. A controlled, randomized, prospective study on a once-a-day therapy for HIV infection. En: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 2002. Abstract H-163.
28. Gazzard BG, De Jesús E, Cahn P, Castillo H, Zhao H, Gordon D, et al. Abacavir once-daily (OAD) plus lamivudine (OAD) in combination with efavirenz (OAD) is well-tolerated and effective in the treatment of antiretroviral therapy naive adults with HIV-1 Infection (ZODIAC Study: CNA30021). 43rd Interscience Conference on Antiretroviral Agents and Chemotherapy. Chicago, Illinois, 2003. Abstract H-1722b.
29. Molina JM, Journot V, Morand-Joubert L, Yéni P, Rozenbaum W, Rancinan C, et al; ALIZE (Agence Nationale de Recherches sur le SIDA 099) Study Team. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis. 2005;191:830-9.
30. Mole L, Schmidgall D, Holodniy M. A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection. J Acquir Immune Defic Syndr. 2001;27:260-5.
31. Gathe J, Podzamczer D, Johnson M, Tressler R, Brun S. Once-daily vs twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, 2004. Abstract 570.
32. Kearney BP, Damle B, Plummer A, Sayre J, Namini H, Ryan K, et al. pharmacokinetics Evaluation of Tenofovir DF and Enteric-Coated Didanosine. Sixth International Congress on Drug Therapy in HIV Infection. Glasgow, 2002. Abstract 186.
33. Gallant JE, Staszewski S, Pozniak AL, De Jesús E, Suleiman JM, Miller MD, et al for the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antirretroviral-naive patients. A 3 year randomized trial. JAMA. 2004;292:191-201.
34. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, et al, for the EMTRICITABINA-301A Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antirretroviral-naïve patients. JAMA. 2004;292:180-90.
35. Katlama C, Rachlis A, Staszewski S, Becker S, Manion DJ, Maa JF, et al. Better virologic suppression after substitution of protease inhibitors with efavirenz in patients with undetectable viral loads. 8th European Conference on Clinic Aspects and Treatment of HIV-Infection. Atenas, 2001. Abstract 06.
36. Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, Mallolas J, et al. TRIZAL study: Switching from successful HAART to trizivir (abacavir-lamivudine- zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med. 2003;4:79-86.
37. Pulido F, Hernando A. Tratamiento antirretroviral de gran actividad administrado una vez al día: ¿presente o futuro? Med Clin (Barc). 2002;121:304-9.
38. Nascimbeni M, Lamotte C, Peytavin G, Farinotti R, Clarel F. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother. 1999;43:2629-34.
39. Dybul M, Nies-Kraske E, Dewar R, Maldarelli F, Hallahan CW, Dancher M, et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis. 2004;189:1974-82.